UNICA IRIS Institutional Research Information System

PRETTA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.502
NA - Nord America 2.407
AS - Asia 1.676
SA - Sud America 269
AF - Africa 40
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 38.901
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 33.733
US - Stati Uniti d'America 2.310
SG - Singapore 696
CN - Cina 557
BR - Brasile 217
SE - Svezia 217
DE - Germania 137
VN - Vietnam 114
GB - Regno Unito 81
FR - Francia 69
IN - India 63
NL - Olanda 62
FI - Finlandia 60
HK - Hong Kong 51
CA - Canada 50
KR - Corea 46
MX - Messico 32
PL - Polonia 25
AT - Austria 22
ES - Italia 21
TR - Turchia 20
IE - Irlanda 17
IQ - Iraq 16
EC - Ecuador 14
IR - Iran 14
JP - Giappone 14
ZA - Sudafrica 13
AE - Emirati Arabi Uniti 12
AR - Argentina 12
BD - Bangladesh 12
BE - Belgio 11
VE - Venezuela 9
PK - Pakistan 8
RU - Federazione Russa 8
UZ - Uzbekistan 7
AU - Australia 6
LT - Lituania 6
MA - Marocco 6
UA - Ucraina 6
CO - Colombia 5
ID - Indonesia 5
TH - Thailandia 5
GR - Grecia 4
NP - Nepal 4
PH - Filippine 4
PY - Paraguay 4
SA - Arabia Saudita 4
BZ - Belize 3
CL - Cile 3
DZ - Algeria 3
KE - Kenya 3
KG - Kirghizistan 3
PE - Perù 3
PT - Portogallo 3
TN - Tunisia 3
TW - Taiwan 3
AM - Armenia 2
AZ - Azerbaigian 2
BB - Barbados 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GA - Gabon 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
NO - Norvegia 2
PA - Panama 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DM - Dominica 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
OM - Oman 1
PS - Palestinian Territory 1
RO - Romania 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 38.901
Salva come PNG Salva come JPEG
Città #
Cagliari 31.576
Uta 1.832
Dallas 521
Ashburn 375
Singapore 342
Boardman 164
Beijing 125
Nyköping 104
Los Angeles 99
Chandler 89
Fairfield 85
Hefei 76
New York 71
Santa Clara 63
Shanghai 49
Hong Kong 48
Seoul 45
Amsterdam 44
Ho Chi Minh City 44
Rome 44
Houston 39
The Dalles 38
Seattle 36
Florence 35
Munich 35
Wilmington 33
Nuremberg 31
Helsinki 30
Redondo Beach 30
Boston 29
Cambridge 28
Frankfurt am Main 28
Woodbridge 26
São Paulo 22
Buffalo 21
Pune 21
Montreal 20
Guangzhou 19
Warsaw 19
San Diego 18
Stockholm 18
Toronto 16
Chennai 15
Chicago 15
Hanoi 15
London 15
Turku 15
Dublin 14
Düsseldorf 14
Lappeenranta 14
Mexico City 14
Poplar 14
Denver 13
Milan 13
Shenzhen 13
Orem 11
Selargius 11
Johannesburg 10
Vienna 10
Manchester 9
Rio de Janeiro 9
Brooklyn 8
Dong Ket 8
Paris 8
Roubaix 8
Wuhan 8
Ankara 7
Atlanta 7
Brussels 7
Dubai 7
Haiphong 7
Istanbul 7
Salt Lake City 7
Tashkent 7
Tokyo 7
Zhengzhou 7
Baghdad 6
Querétaro 6
Quito 6
San Francisco 6
Scandicci 6
Tianjin 6
Bexley 5
Casablanca 5
Clifton 5
Forlì 5
Jacksonville 5
Lauterbourg 5
Menlo Park 5
New Delhi 5
Olbia 5
Phoenix 5
Portsmouth 5
Sassari 5
Tehran 5
Ann Arbor 4
Belo Horizonte 4
Biên Hòa 4
Campinas 4
Charlotte 4
Totale 36.863
Salva come PNG Salva come JPEG
Nome #
BRAF-mutant colorectal cancer, a different breed evolving 3.212
Molecular-biology-driven treatment for metastatic colorectal cancer 2.718
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.327
New therapeutic targets in pancreatic cancer 1.593
Immunotherapy and Cancer: The Multi-Omics Perspective 1.557
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.491
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.308
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.184
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.137
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 1.009
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.006
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 946
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 910
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 904
Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer 902
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 901
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 865
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 816
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 744
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 715
Uncovering key targets of success for immunotherapy in pancreatic cancer 680
Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer 675
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 670
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 636
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 624
BRCA-mutant pancreatic ductal adenocarcinoma 584
Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy 577
Immune Checkpoint Inhibitors in the Treatment of HCC 552
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 544
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 530
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 514
Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects 481
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 437
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 411
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 405
CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects 314
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 302
Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas 298
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score 253
Artificial Intelligence Models for the Detection of Microsatellite Instability from Whole-Slide Imaging of Colorectal Cancer 241
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 240
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 222
CD44: A New Prognostic Marker in Colorectal Cancer? 212
A new prognostic score for biliary tract cancer: a multicenter experience 194
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 175
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 154
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 151
Medical management of malignant bowel obstruction: our center experience 151
Early taxane exposure and neurotoxicity in breast cancer patients 150
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 149
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 148
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients 134
Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors 125
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 120
Cancer-associated fibroblasts (CAFs) and plaque-associated fibroblasts (PAFs): Unraveling the cellular crossroads of atherosclerosis and cancer 115
Exercise Prescription in Cardio-Oncology 75
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 69
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 67
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 59
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 57
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 55
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 53
The impact of surgical resection in early onset colorectal cancer patients with liver limited disease 53
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 51
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 47
The role of metastasectomy in patients with early onset metastatic colorectal cancer 45
The impact of the fetal exposome as a predictor of cancer risk in childhood and adulthood. Aberrant epigenetic events occurring during gestation: May they trigger fetal programming of cancer risk later in life? 44
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon 20
Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial 8
Treatment compliance in early-stage anal cancer 7
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel 3
Abstract 28: Prognostic value of baseline and early changes of circulating cell-free (cf)DNA in the neoadjuvant setting of early stage colon cancer (CC) 3
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials 3
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer 2
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial 2
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer 1
Totale 39.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.457
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.457
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.869 0 0 0 0 0 530 186 310 140 289 252 162
2021/20222.042 127 87 24 97 119 135 96 187 170 229 334 437
2022/20235.037 400 643 563 372 376 438 226 391 428 528 441 231
2023/20245.556 261 184 185 280 429 859 960 424 371 351 576 676
2024/202517.561 5.035 5.672 1.555 1.659 786 1.105 805 104 197 185 149 309
2025/20263.364 499 410 791 646 535 483 0 0 0 0 0 0
Totale 39.137